Add to ORKGAtherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition
The transition from stable to rupture-prone and ruptured atherosclerotic plaques involves many proce...
ObjectivesWe investigated whether simvastatin attenuates plaque inflammation by using 18F-fluorodeox...
Lipid-lowering therapy reduces cardiovascular morbidity and mortality. Although atherosclerotic plaq...
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and compositi...
Aims Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in athero...
Cardiovascular diseases are responsible for over 50% of all deaths in Western society, with the unde...
Objective: To investigate the effect of S18886, a novel TP (thromboxane A2 and prostaglandin endoper...
Thromboxane A 2 and the activation of TP receptors that it causes play an important role in platelet...
Atherosclerosis follows the deposition, retention, and oxidative modification of lipoproteins, espec...
<p>The effects of broad-spectrum chemokine inhibition by M3 was demonstrated via two models of ather...
Background—S18886 is an orally active thromboxane A2 (TXA2) receptor (TP) antagonist in clinical dev...
ObjectivesThis study sought to assess the effect of short-term apolipoprotein (apo) A-IMilano admini...
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in pat...
<div><p>Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was foun...
Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor (TF)-mediated coagulat...
The transition from stable to rupture-prone and ruptured atherosclerotic plaques involves many proce...
ObjectivesWe investigated whether simvastatin attenuates plaque inflammation by using 18F-fluorodeox...
Lipid-lowering therapy reduces cardiovascular morbidity and mortality. Although atherosclerotic plaq...
Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and compositi...
Aims Endothelial dysfunction, platelet hyperactivity, and inflammation play a crucial role in athero...
Cardiovascular diseases are responsible for over 50% of all deaths in Western society, with the unde...
Objective: To investigate the effect of S18886, a novel TP (thromboxane A2 and prostaglandin endoper...
Thromboxane A 2 and the activation of TP receptors that it causes play an important role in platelet...
Atherosclerosis follows the deposition, retention, and oxidative modification of lipoproteins, espec...
<p>The effects of broad-spectrum chemokine inhibition by M3 was demonstrated via two models of ather...
Background—S18886 is an orally active thromboxane A2 (TXA2) receptor (TP) antagonist in clinical dev...
ObjectivesThis study sought to assess the effect of short-term apolipoprotein (apo) A-IMilano admini...
Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was found in pat...
<div><p>Abnormal expression of thymic stromal lymphopoietin (TSLP) and its receptor (TSLPR) was foun...
Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor (TF)-mediated coagulat...
The transition from stable to rupture-prone and ruptured atherosclerotic plaques involves many proce...
ObjectivesWe investigated whether simvastatin attenuates plaque inflammation by using 18F-fluorodeox...
Lipid-lowering therapy reduces cardiovascular morbidity and mortality. Although atherosclerotic plaq...